Loading…
Company's IP and market exclusivity support combination therapies.
STRATA Skin Sciences, Inc. announced on September 2, 2025, that its patent portfolio provides intellectual property (IP) and market exclusivity for combination therapies involving its XTRAC excimer laser with JAK inhibitors, systemic, and biologic drugs. This development supports the company's expansion into new indications such as vitiligo and other autoimmune skin conditions.
The announcement highlights the strategic importance of the company's patent portfolio in protecting its innovative combination therapies. With 2,886,400 shares in free float and 5,888,200 shares outstanding, STRATA Skin Sciences is well-positioned to leverage its IP advantages in the medical devices industry.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.